Truist Reaffirms Buy Rating on Eli Lilly Following Positive Trial Results for Foundayo
Truist Securities reaffirmed its 'Buy' rating and $1,281 price target for Eli Lilly (LLY) following positive Phase 3 trial results of the drug Foundayo in treating type 2 diabetes. The ACHIEVE-4 study showed no inferiority to insulin glargine with a reduced risk of all-cause death.
Topics: Eli Lilly FDA approval Foundayo Phase 3 trials type 2 diabetes